Cognitive-motor impairment and disorder in HIV-1 infection

Psychiatric Annals

Volumn 31, Issue 1, 2001, Pages 37-44

  Goodkin, Karl ^a,b   Baldewicz, Teri T ^a   Wilkie, Frances L ^a   Tyll, Mary D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044524868     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20010101-09     Document Type: Article

References (47)

1. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998;10:125-132.
2. Grant I, Heaton RK, Ellis RO, et al. Neurocognitive complications in HIV. Presented at the XIIth International Conference on AIDS; 1998; Geneva, Switzerland. Abstract.
3. Simpson DM. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clin Infect Dis. 1999;29:19-34.
4. Ferrando S, vanGorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12:F65-F70.
5. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol. 1996;2:404-410.
6. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13:1249-1253.
7. American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology. 1991;41:778-785.
8. Wilkie FL, Eisdorfer C, Morgan R, Lowenstein DA, Szapocznik J. Cognition in early human immunodeficiency virus infection. Arch Neurol. 1990;47:433-440.
9. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. Neurology. 1996;47: 1247-1253.
10. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:59-68.
11. Arendt G, Hefter H, Figge C, et al. Two cases of cerebral toxoplasmosis in AIDS patients mimicking HIV-related dementia. J Neurol. 1991;238:439-442.
12. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol. 1990; 47:640-642.
13. Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. Am J Psychiatry. 1994;151:237-242.
14. Goodkin K, Blaney NT, Tuttle RS, et al. Bereavement and HIV infection. Int Rev Psychiatry. 1996;8:201-216.
15. Rush AJ, Weissenburger J, Vinson DB, Giles DE. Neuropsychological dysfunctions in unipolar nonpsychotic major depressions. J Affect Disord. 1983;5:281-287.
16. Channon S, Green PS. Executive function in depression: the role of performance strategies in aiding depressed and non-depressed participants. J Neurol Neurosurg Psychiatry. 1999;66:162-171.
17. Asthana HS, Mandal MK, Khurana H, Haque-Nizamie S. Visuospatial and affect recognition deficit in depression. J Affect Disord. 1998;48:57-62.
18. Dolan RJ, Bench CJ, Brown RG, Scott LC, Frackowiak RS. Neuropsychological dysfunction in depression: the relationship to regional cerebral blood flow. Psychol Med. 1994;24:849-857.
19. Wilkie FL, Goodkin K. Cognitive function in HIV infection. In: Goodkin K, Visser AP, eds. Psychoneuroimmunology: Stress, Mental Disorders and Health. Washington, DC: American Psychiatric Press; 2000:231-290.
20. Bell JE, Donaldson YK, Lowrie S, et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS. 1996;10:493-499.
21. Fletcher JM, Page JB, Francis DJ, et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry. 1996;53:1051-1057.
22. Goodkin K, Shapshak P, Metsch LR, et al. Cocaine abuse and HIV-1 infection: epidemiology and neuropathogenesis. J Neuroimmunol. 1998;83:88-101.
23. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled clinical trial. AIDS Clinical Trials Group. Ann Neurol. 1993;33:343-349.
24. Montforte A, Musicco M, Galli M, et al. Italian multicenter study of didanosine compassionate use in advanced HIV infection. Eur J Microb Infect Dis. 1997;16:135-142.
25. Pizzo PA, Butler K, Balis F, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1990;117:799-808.
26. McIntyre K, Torres R, Luck D, Tavalouras G. Pilot study of zidovudine (AZT) and zalcitabine (ddC) combination in HIV-associated dementia. Presented at the Tenth International Conference on AIDS; 1994; Yokohama, Japan. Abstract.
27. Brew BJ, Brown SJ, Catalan J, et al. Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex. Presented at the XIIth International Conference on AIDS; 1998; Geneva, Switzerland. Abstract.
28. Thomas SA, Segal MB. The transport of the anti-HIV drug, 2′,3′-didehydro-3′-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br J Pharmacol. 1998;125:49-54.
29. Goodkin K, Wilkie FL, Concha M, et al. Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection: neuroradiological, neurophysiological, neuroimmunological, and virological correlates. Neuroimaging Clin N Am. 1997;7:561-579.
30. Stahle L, Martin C, Svensson JO, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1 infected patients. Lancet. 1997;350:1823.
31. Galgani S, Narciso P, Balestra P, et al. Nimodipine + AZT in patients with ADC. Presented at the Tenth International Conference on AIDS; 1994; Yokohama, Japan. Abstract.
32. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related complications. Neurology. 1998;51:221-228.
33. Heseltine PN, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of Peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55:41-51.
34. Kosten TR, Rosen MI, McMahon TL, et al. Treatment of early AIDS dementia in intravenous drug users: high versus low peptide T. Am J Drug Alcohol Abuse. 1997;23:543-553.
35. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996;47:1254-1259.
36. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci. 1996;8:74-81.
37. Fernandez F, Adams F, Levy JK, Holmes VF, Neidhart M, Mansell PW. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics. 1988;29:38-46.
38. Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry. 1989;50:5-8.
39. Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex: therapeutic implications. Arch Neurol. 1991;48:1281-1284.
40. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology. 1998;50:645-651.
41. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 1994;10:947-951.
42. Navia BA, Khan A, Pumarola-Sune T, Price RW. Choline aceryltransferase activity is reduced in the AIDS dementia complex. Ann Neurol. 1986;20:142.
43. Shor-Posner G, Morgan R, Wilkie F, Eisdorfer C, Baum MK. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neurol. 1995;52:195-198.
44. Herzlich BC, Schiano TD. Reversal of apparent AIDS dementia complex following treatment with vitamin B12. J Intern Med. 1993;233:495-497.
45. Baldewicz T, Goodkin K, Feaster DJ, et al. Plasma pyridoxine deficiency is related to increased psychological distress in recently bereaved homosexual men. Psychosom Med. 1998;60:297-308.
46. Baldewicz TT, Brouwers P, Goodkin K, et al. Nutritional contributions to the CNS pathophysiology of HIV infection and implications for treatment. Int J Neuropsychiatric Med. 2000. In press.
47. Auerbach V, Jann B. Neurorehabilitation and HIV infection: clinical and ethical dilemmas. J Head Trauma Rehabil. 1989;4:23-31.